{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:51:21Z","timestamp":1787503881276,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013993","name":"Theravance Biopharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013993","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006537","name":"Vanderbilt University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009999","name":"Center for African Studies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009999","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000222","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000222","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["autonomicneuroscience.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autonomic Neuroscience"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.autneu.2019.05.002","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T08:15:15Z","timestamp":1578557715000},"page":"102550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Human papillomavirus (HPV) vaccine and autonomic disorders: a position statement from the American Autonomic Society"],"prefix":"10.1016","volume":"223","author":[{"given":"Alexandru","family":"Barboi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Axelrod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo E.","family":"Benarroch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Italo","family":"Biaggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Chapleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Chelimsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Chelimsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Cheshire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria E.","family":"Claydon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Joyner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horacio","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip A.","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Norcliffe-Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyndya A.","family":"Shibao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Snapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Vernino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish R.","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.autneu.2019.05.002_bb0005","first-page":"630","article-title":"FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"(CDC) CfDCaP","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"20","key":"10.1016\/j.autneu.2019.05.002_bb0010","first-page":"626","article-title":"FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"(CDC) CfDCaP","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"6","key":"10.1016\/j.autneu.2019.05.002_bb0015","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.vaccine.2017.01.007","article-title":"Human papillomavirus vaccine series completion in boys before and after recommendation for routine immunization","volume":"35","author":"Ackerson","year":"2017","journal-title":"Vaccine."},{"issue":"13","key":"10.1016\/j.autneu.2019.05.002_bb0020","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.vaccine.2017.01.076","article-title":"No increased risk of Guillain-Barr\u00e9 syndrome after human papilloma virus vaccine: a self-controlled case-series study in England","volume":"35","author":"Andrews","year":"2017","journal-title":"Vaccine."},{"key":"10.1016\/j.autneu.2019.05.002_bb0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.critrevonc.2016.03.020","article-title":"Ten years of HPV vaccines: state of art and controversies","volume":"102","author":"Angioli","year":"2016","journal-title":"Crit Rev Oncol Hematol."},{"issue":"5","key":"10.1016\/j.autneu.2019.05.002_bb0030","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jadohealth.2017.08.004","article-title":"Reports of postural orthostatic tachycardia syndrome after human papillomavirus vaccination in the vaccine adverse event reporting system","volume":"61","author":"Arana","year":"2017","journal-title":"J. Adolesc. Health"},{"issue":"9","key":"10.1016\/j.autneu.2019.05.002_bb0035","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1517\/14740338.2015.1073710","article-title":"The safety ofhuman papilloma virus-blockers and the risk of triggering autoimmune diseases","volume":"14","author":"Baker","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"issue":"1","key":"10.1016\/j.autneu.2019.05.002_bb0040","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/ene.12272","article-title":"Postural tachycardia syndrome following human papillomavirus vaccination","volume":"21","author":"Blitshteyn","year":"2014","journal-title":"Eur. J. Neurol."},{"issue":"Suppl. 7","key":"10.1016\/j.autneu.2019.05.002_bb0045","doi-asserted-by":"crossref","first-page":"H1","DOI":"10.1016\/j.vaccine.2013.10.003","article-title":"Comprehensive control of human papillomavirus infections and related diseases","volume":"31","author":"Bosch","year":"2013","journal-title":"Vaccine."},{"issue":"38","key":"10.1016\/j.autneu.2019.05.002_bb0050","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1016\/j.vaccine.2016.05.035","article-title":"Response to letter to the editor","volume":"34","author":"Brinth","year":"2016","journal-title":"Vaccine."},{"issue":"22","key":"10.1016\/j.autneu.2019.05.002_bb0055","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1016\/j.vaccine.2015.03.098","article-title":"Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus","volume":"33","author":"Brinth","year":"2015","journal-title":"Vaccine."},{"issue":"12","key":"10.1016\/j.autneu.2019.05.002_bb0060","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1086\/657321","article-title":"Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings","volume":"202","author":"Bruni","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.autneu.2019.05.002_bb0065","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cbpa.2016.03.001","article-title":"Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine","volume":"32","author":"Bryan","year":"2016","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"11","key":"10.1016\/j.autneu.2019.05.002_bb0070","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1177\/0883073817718731","article-title":"Human papillomavirus vaccine and postural orthostatic tachycardia syndrome: a review of current literature","volume":"32","author":"Butts","year":"2017","journal-title":"J. Child Neurol."},{"issue":"4","key":"10.1016\/j.autneu.2019.05.002_bb0075","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/imj.13005","article-title":"Adverse event monitoring of the human papillomavirus vaccines in Scotland","volume":"46","author":"Cameron","year":"2016","journal-title":"Intern. Med. J."},{"issue":"6","key":"10.1016\/j.autneu.2019.05.002_bb0080","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.3892\/ijo.2014.2355","article-title":"Human papillomavirus and oropharyngeal cancer, the epidemics, and significance of additional clinical biomarkers for prediction of response to therapy (review)","volume":"44","author":"Dalianis","year":"2014","journal-title":"Int. J. Oncol."},{"issue":"8","key":"10.1016\/j.autneu.2019.05.002_bb0085","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/10810730.2017.1337832","article-title":"Making vaccine messaging stick: perceived causal instability as a barrier to effective vaccine messaging","volume":"22","author":"Dixon","year":"2017","journal-title":"J. Health Commun."},{"issue":"43","key":"10.1016\/j.autneu.2019.05.002_bb0090","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1016\/j.vaccine.2013.08.024","article-title":"Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK","volume":"31","author":"Donegan","year":"2013","journal-title":"Vaccine."},{"issue":"2","key":"10.1016\/j.autneu.2019.05.002_bb0095","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/path.4656","article-title":"Model systems of human papillomavirus-associated disease","volume":"238","author":"Doorbar","year":"2016","journal-title":"J. Pathol."},{"key":"10.1016\/j.autneu.2019.05.002_bb0100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bpobgyn.2017.08.001","article-title":"Host control of human papillomavirus infection and disease","volume":"47","author":"Doorbar","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol."},{"issue":"Suppl. 1","key":"10.1016\/j.autneu.2019.05.002_bb0105","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/rmv.1822","article-title":"Human papillomavirus molecular biology and disease association","volume":"25","author":"Doorbar","year":"2015","journal-title":"Rev. Med. Virol."},{"issue":"5","key":"10.1016\/j.autneu.2019.05.002_bb0110","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infect. Dis."},{"issue":"Suppl. 5","key":"10.1016\/j.autneu.2019.05.002_bb0115","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30","author":"Forman","year":"2012","journal-title":"Vaccine."},{"issue":"2","key":"10.1016\/j.autneu.2019.05.002_bb0120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10286-011-0119-5","article-title":"Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome","volume":"21","author":"Freeman","year":"2011","journal-title":"Clin. Auton. Res."},{"issue":"6","key":"10.1016\/j.autneu.2019.05.002_bb0125","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1080\/21645515.2016.1168952","article-title":"Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States","volume":"12","author":"Gee","year":"2016","journal-title":"Hum Vaccin Immunother."},{"key":"10.1016\/j.autneu.2019.05.002_bb0130","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jaut.2017.01.005","article-title":"Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: six years of case-referent surveillance","volume":"79","author":"Grimaldi-Bensouda","year":"2017","journal-title":"J. Autoimmun."},{"issue":"4","key":"10.1016\/j.autneu.2019.05.002_bb0135","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jca.21407","article-title":"Complex regional pain syndrome and dysautonomia in a 14-year-old girl responsive to therapeutic plasma exchange","volume":"31","author":"Hendrickson","year":"2016","journal-title":"J. Clin. Apher."},{"issue":"2","key":"10.1016\/j.autneu.2019.05.002_bb0140","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/CVI.05208-11","article-title":"Immunogenicity of the quadrivalent human papillomavirus (type 6\/11\/16\/18) vaccine in males 16 to 26 years old","volume":"19","author":"Hillman","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.autneu.2019.05.002_bb0145","series-title":"Centers for Disease Control and Prevention. Epidemiology and Prevention of vaccine preventable diseases","first-page":"175","author":"In","year":"2015"},{"issue":"18","key":"10.1016\/j.autneu.2019.05.002_bb0150","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.vaccine.2017.03.015","article-title":"Consensus statement from 17 relevant Japanese academic societies on the promotion of the human papillomavirus vaccine","volume":"35","author":"Iwata","year":"2017","journal-title":"Vaccine."},{"issue":"10","key":"10.1016\/j.autneu.2019.05.002_bb0155","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1002\/cncr.27988","article-title":"Synchronous cancers in patients with head and neck cancer: risks in the era of human papillomavirus-associated oropharyngeal cancer","volume":"119","author":"Jain","year":"2013","journal-title":"Cancer."},{"issue":"2","key":"10.1016\/j.autneu.2019.05.002_bb0160","first-page":"502","article-title":"Detection Of Human Papilloma Virus In Head And Neck Squamous Cell Carcinomas: a literature review","volume":"119","author":"Jelihovschi","year":"2015","journal-title":"Rev. Med. Chir. Soc. Med. Nat. Iasi"},{"key":"10.1016\/j.autneu.2019.05.002_bb0165","series-title":"What the Gardasil testing may have missed","author":"Joelving","year":"2017"},{"issue":"3","key":"10.1016\/j.autneu.2019.05.002_bb0170","doi-asserted-by":"crossref","first-page":"492","DOI":"10.4103\/0973-1482.138213","article-title":"Exploring the link between human papilloma virus and oral and oropharyngeal cancers","volume":"10","author":"Khode","year":"2014","journal-title":"J. Cancer Res. Ther."},{"issue":"28","key":"10.1016\/j.autneu.2019.05.002_bb0175","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1016\/j.vaccine.2011.04.050","article-title":"Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)- 16\/18 vaccine in the Netherlands","volume":"29","author":"van Klooster","year":"2011","journal-title":"Vaccine."},{"issue":"21","key":"10.1016\/j.autneu.2019.05.002_bb0180","doi-asserted-by":"crossref","first-page":"E648","DOI":"10.1503\/cmaj.170871","article-title":"Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV Vaccine Cohort Study","volume":"190","author":"Liu","year":"2018","journal-title":"CMAJ."},{"issue":"6","key":"10.1016\/j.autneu.2019.05.002_bb0185","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40264-013-0039-5","article-title":"Safety of human papillomavirus vaccines: a review","volume":"36","author":"Macartney","year":"2013","journal-title":"Drug Saf."},{"issue":"RR-2","key":"10.1016\/j.autneu.2019.05.002_bb0190","first-page":"1","article-title":"Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP)","volume":"56","author":"Markowitz","year":"2007","journal-title":"MMWR Recomm. Rep."},{"issue":"7","key":"10.1016\/j.autneu.2019.05.002_bb0195","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s10067-015-2969-z","article-title":"Hypothesis: human papillomavirus vaccination syndrome--small fiber neuropathy and dysautonomia could be its underlying pathogenesis","volume":"34","author":"Mart\u00ednez-Lav\u00edn","year":"2015","journal-title":"Clin. Rheumatol."},{"issue":"36","key":"10.1016\/j.autneu.2019.05.002_bb0200","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1016\/j.vaccine.2017.07.113","article-title":"Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: a literature review","volume":"36","author":"Maver","year":"2018","journal-title":"Vaccine."},{"issue":"28","key":"10.1016\/j.autneu.2019.05.002_bb0205","first-page":"393","article-title":"7\u20138 June 2017","volume":"92","author":"Meeting of the Global Advisory Committee on Vaccine Safety","year":"2017","journal-title":"Wkly Epidemiol Rec."},{"issue":"36","key":"10.1016\/j.autneu.2019.05.002_bb0210","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1016\/j.vaccine.2017.06.030","article-title":"Human papillomavirus vaccination and risk of autoimmune diseases: a large cohort study of over 2million young girls in France","volume":"35","author":"Miranda","year":"2017","journal-title":"Vaccine."},{"issue":"9","key":"10.1016\/j.autneu.2019.05.002_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162520","article-title":"Pre-vaccination care-seeking in females reporting severe adverse reactions to HPV vaccine. A registry based case-control study","volume":"11","author":"M\u00f8lbak","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.autneu.2019.05.002_bb0220","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/jpids\/piy070","article-title":"Update from the advisory committee on immunization practices","volume":"7","author":"O'Leary","year":"2018","journal-title":"J Pediatric Infect Dis Soc."},{"issue":"3","key":"10.1016\/j.autneu.2019.05.002_bb0225","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s10067-015-3090-z","article-title":"Proposed HPV vaccination syndrome is unsubstantiated","volume":"35","author":"Petousis-Harris","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.autneu.2019.05.002_bb0230","unstructured":"Pharmacovigilance Risk Assessment Committee EMA. Assessment report. Review under Article 20 of Regulation (EC) No. 726\/2004. Human Papillomavirus (HPV) Vaccines. London, United Kingdom 2015 http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/HPV_vaccines_20\/Opinion_provided_by_Committee_for_Medicinal_Products_for_Human_Use\/WC500197129.pdf Accessed May 2018."},{"issue":"4","key":"10.1016\/j.autneu.2019.05.002_bb0235","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40264-017-0625-z","article-title":"Safety of human papillomavirus vaccines: an updated review","volume":"41","author":"Phillips","year":"2018","journal-title":"Drug Saf."},{"issue":"5","key":"10.1016\/j.autneu.2019.05.002_bb0240","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1503\/cmaj.070948","article-title":"Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials","volume":"177","author":"Rambout","year":"2007","journal-title":"CMAJ."},{"issue":"43","key":"10.1016\/j.autneu.2019.05.002_bb0245","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1016\/j.vaccine.2017.05.069","article-title":"WHOEa. Human papillomavirus vaccines: WHO position paper, May 2017-recommendations","volume":"35","author":"sageexecsec@who.int","year":"2017","journal-title":"Vaccine."},{"issue":"9590","key":"10.1016\/j.autneu.2019.05.002_bb0250","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","article-title":"Human papillomavirus and cervical cancer","volume":"370","author":"Schiffman","year":"2007","journal-title":"Lancet."},{"issue":"Suppl. 5","key":"10.1016\/j.autneu.2019.05.002_bb0255","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30","author":"Schiller","year":"2012","journal-title":"Vaccine."},{"key":"10.1016\/j.autneu.2019.05.002_bb0260","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pvr.2017.03.001","volume":"3","author":"Skufca","year":"2017","journal-title":"Papillomavirus Res."},{"issue":"8","key":"10.1016\/j.autneu.2019.05.002_bb0265","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.vaccine.2018.01.018","article-title":"Systematic causality assessment of adverse events following HPV vaccines: analysis of current data from Apulia region (Italy)","volume":"36","author":"Tafuri","year":"2018","journal-title":"Vaccine."},{"key":"10.1016\/j.autneu.2019.05.002_bb0270","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jneuroim.2016.07.003","article-title":"Immunological studies of cerebrospinal fluid from patients with CNS symptoms after human papillomavirus vaccination","volume":"298","author":"Takahashi","year":"2016","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.autneu.2019.05.002_bb0275","article-title":"Postural orthostatic tachycardia with chronic fatigue after HPV vaccination as part of the \u201cautoimmune\/auto-inflammatory syndrome induced by adjuvants\u201d","volume":"2","author":"Tomljenovic","year":"2014","journal-title":"Case Report and Literature Review. J Investig Med High Impact Case Rep."},{"key":"10.1016\/j.autneu.2019.05.002_bb0280","series-title":"Causality Assessment of an Adverse Event Following Immunization (AEFI): User Manual for the Revised WHO Classification","author":"Works Health Organization","year":"2018"}],"container-title":["Autonomic Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156607021930116X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156607021930116X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:14:14Z","timestamp":1761567254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156607021930116X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":56,"alternative-id":["S156607021930116X"],"URL":"https:\/\/doi.org\/10.1016\/j.autneu.2019.05.002","relation":{},"ISSN":["1566-0702"],"issn-type":[{"value":"1566-0702","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human papillomavirus (HPV) vaccine and autonomic disorders: a position statement from the American Autonomic Society","name":"articletitle","label":"Article Title"},{"value":"Autonomic Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autneu.2019.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102550"}}